Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH — Clinical Trial Site

16 Registered trials

3 Currently recruiting

Organisation

Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH

Location

Berlin, Germany

Identifier

ORG-100043718

Address

Budapester Straße 15-19, Tiergarten, 10787, Germany

Departments

2003; NA
Department of Infectious Diseases, Sankt Joseph Hospital Berlin
Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbh
Im Franziskus-Krankenhaus
n/a
NA

Clinical trials at this site (16)

Search interface

A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi… Not authorised

2022-502099-22-00 HIV-1 Infection 5
A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravir Not authorised

2022-502126-40-00 HIV-1 infection 5
A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-re… Recruiting

2024-511596-15-00 Liver Diseases, Alcoholic 4 2024-12-26
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re… Recruiting

2022-502972-22-00 Clostridioides difficile infection. 5 2024-10-31
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho… Recruiting

2023-505141-48-00 Fibrosis 5 2024-03-07
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended

2025-521918-26-00 HIV Infections 4 2026-02-11
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppres… Ended

2024-514046-37-00 HIV-1 Infection 5 2025-01-16
A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended

2023-504993-40-00 Human immunodeficiency virus (HIV) 5 2024-02-14
A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr… Ended

2022-502102-32-00 Primary Immunoglobulin A (IgA) Nephropathy 5 2023-11-16
Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended

2023-506867-33-01 Chronic Hepatitis B 4 2022-01-25
A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended

2023-508248-23-00 Non-alcoholic steatohepatitis (NASH) 5 2021-11-26
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age Ended

2022-501974-21-00 Prevention of oral persistent infection caused by any o 5 2020-04-01
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and… Ended

2024-510626-89-00 Non-Alcoholic Steatohepatitis (NASH) 5 2019-11-18
A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased … Ended

2023-510190-34-00 Respiratory Syncytial Virus Infections 5 2024-06-04
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended

2023-504239-41-00 Hepatitis B, Chronic 5 2023-01-09
A study on the safety, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide against chronic Hepati… Ended

2024-512352-38-00 Hepatitis B, Chronic 4 2019-03-28